Login
Alector, Inc. logo

Alector, Inc.

alector.com

What Do They Do?

Develops investigational antibody, enzyme, and siRNA therapies for neurodegenerative diseases, including Alzheimer’s and Parkinson’s, for patients.

How Do They Make Money?

Alector has not earned money from product sales; revenue has come mainly from partners licensing and co-developing product candidates. AbbVie payments were spread over the work, while GSK paid an upfront amount for a development license and for research and development services as those services were performed.

FY2025 revenue

Who Are Their Customers?

Biopharmaceutical partners such as GSK and AbbVie have paid Alector under licensing and co-development agreements for product candidates.

Do Revenues Turn Into Profits?

No. It lost $142.9M in FY2025.

Operating income, FY2025
−741% of revenue
▼ −8% (Loss) vs FY2024 (−$145M, −144%)
Net income, FY2025
−679% of revenue
▼ −20% (Loss) vs FY2024 (−$119M, −118%)
Free cash flow, FY2025
−875% of revenue
▲ +20% (Loss) vs FY2024 (−$231.2M, −230%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +4896%
vs $3.3M in Q3 FY2025
Net income
▲ Turned profitable
vs −$34.7M in Q3 FY2025
  • Jul 8, 2026 GSK gave notice to terminate its collaboration agreement The termination is scheduled to take effect on January 2, 2027, following the discontinuation of the nivisnebart trial and the earlier result of the latozinemab trial.

Shrinking. Revenue fell 90% in 4 years, from $207.1M in FY2021 to $21M in FY2025, about 44% a year.

A narrower disease focus The older report described programs for neurodegenerative diseases and oncology, including immuno-oncology candidates. The latest report focuses its described pipeline on neurodegenerative diseases and brain-delivery programs.

From immune-centered therapies to delivery technology The older report framed the approach around harnessing the brain’s immune system. The latest report emphasizes targeted mechanisms and its brain-delivery platform across antibodies, enzymes, and siRNA.

Who Do They Compete With?

Competes with Biogen, Eli Lilly, Merck, Roche, and Eisai

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support